Consequently, we treated the INSL5‐overexpressing NPC PDX mouse model with anti‐INSL5 and anti‐GPCR142 neutralizing antibodies, and as expected, these treatments markedly inhibited tumor growth. This evidence concerns the gene INSL5 and nasopharyngeal carcinoma.